Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Br J Cancer. 2020 Sep;123(5):694-697. doi: 10.1038/s41416-020-0948-x. Epub 2020 Jun 22.

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anticoagulants / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / physiopathology
  • Coronavirus Infections / virology
  • Drug Repositioning / methods*
  • Humans
  • Immunologic Factors / therapeutic use
  • Inflammation / drug therapy
  • Interleukin-6 / antagonists & inhibitors
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / physiopathology
  • Pneumonia, Viral / virology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Protein Kinase Inhibitors / therapeutic use
  • SARS-CoV-2
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Anticoagulants
  • Antineoplastic Agents
  • IL6 protein, human
  • Immunologic Factors
  • Interleukin-6
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Protein Kinase Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A